Endogenous opioids and hypogonadism in human obesity

Area of Science:

• Endocrinology
• Reproductive Medicine
• Obesity Research

Background:

• Massively obese males frequently exhibit hypogonadism, a condition with an unclear underlying mechanism.
• A proposed mechanism involves increased endogenous opioid inhibition of the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator, leading to insufficient pituitary gonadotroph stimulation.

Purpose of the Study:

• To investigate the etiology of obesity-related hypogonadism.
• To examine luteinizing hormone (LH) and follicle-stimulating hormone (FSH) responses to GnRH and naloxone infusions in obese and normal-weight males.

Main Methods:

• Five massively obese males (201% IBW) and five normal-weight males (97% IBW) were studied.
• Hormonal levels (testosterone, estradiol, androstenedione, dehydroepiandrosterone) were measured.
• Responses to GnRH stimulation and infusions of saline or naloxone were assessed by measuring LH and FSH levels.

Main Results:

• Obese males had significantly lower basal testosterone levels compared to controls.
• Both groups showed similar LH elevations after GnRH, but obese males had lower basal and GnRH-stimulated FSH levels.
• Naloxone infusion significantly increased LH levels in both groups, with obese subjects showing a greater augmentation of integrated LH compared to saline infusion.

Conclusions:

• Obese males exhibit altered gonadotropin responses and are more sensitive to the LH-elevating effects of naloxone, supporting the hypothesis of increased opioid inhibition.
• These findings suggest that obesity-related hypogonadism may be partly mediated by endogenous opioid pathways.
• Naloxone's efficacy in increasing LH in obese males indicates a potential therapeutic target for managing hypogonadism in obesity.